Search results for "Venous Thromboembolism"
Embedded risk assessment tool increased appropriateness of VTE prophylaxis
Physicians used the optional tool embedded in their order set on only 24% of general medical patients, but the rate of appropriate venous thromboembolism (VTE) prophylaxis nonetheless increased from 43.1% to 48.8%.
https://acphospitalist.acponline.org/archives/2024/02/14/embedded-risk-assessment-tool-increased-appropriateness-of-vte-prophylaxis.htm
14 Feb 2024
Apixaban associated with less bleeding than warfarin for VTE in end-stage kidney disease
The use of apixaban among dialysis patients being treated for acute venous thromboembolism (VTE) rose from 2% in 2014 to 47% in 2018, according to an industry-funded retrospective comparison of the drug with warfarin.
https://acphospitalist.acponline.org/archives/2022/08/17/apixaban-associated-with-less-bleeding-than-warfarin.htm
17 Aug 2022
Guidelines updated on use of antithrombotics for VTE
CHEST modified its 2016 recommendations on venous thromboembolism (VTE) management, with changes including the addition of cerebral vein thrombosis as a topic and strengthened support for outpatient VTE treatment.
https://acphospitalist.acponline.org/weekly/archives/2021/08/11/2.htm
11 Aug 2021
New guidelines cover VTE prophylaxis, diagnosis, anticoagulation, and HIT
Several guidelines related to venous thromboembolism (VTE) prevention and treatment were recently published by the American Society of Hematology, with more promised soon.
https://acphospitalist.acponline.org/weekly/archives/2018/12/05/1.htm
5 Dec 2018
Rivaroxaban at discharge did not significantly reduce deaths due to VTE, study finds
Patients who were randomized to 45 days of rivaroxaban instead of placebo did have lower risk of nonfatal venous thromboembolism (VTE), the industry-funded trial found.
https://acphospitalist.acponline.org/weekly/archives/2018/08/29/1.htm
29 Aug 2018
Aspirin, rivaroxaban similarly effective at preventing VTE after total hip or total knee arthroplasty
The trial had a number of limitations, including inclusion of few patients at very high risk of a clot, but the results are still likely to be practice-changing, according to an accompanying editorial.
https://acphospitalist.acponline.org/weekly/archives/2018/02/28/1.htm
28 Feb 2018
Major bleeding, mortality risks after VTE similar on DOACs or warfarin
The authors noted that the safety of DOAC treatment of VTE beyond 180 days remains uncertain and that 95% of DOAC users in the study were taking rivaroxaban, so further study of other agents is needed.
https://acphospitalist.acponline.org/weekly/archives/2017/10/25/3.htm
25 Oct 2017
Outcomes of limited cancer screening after unprovoked VTE similar to extensive screening
The prevalence of cancer after venous thromboembolism (VTE) was low in young patients and women receiving estrogen, leading the study authors to question whether screening for occult cancer should be offered to low-risk patients.
https://acphospitalist.acponline.org/weekly/archives/2017/08/23/1.htm
23 Aug 2017
Rivaroxaban reduced recurrence of unprovoked VTE compared to warfarin
The results support and expand on the findings of previous clinical trials and observational studies of rivaroxaban, by looking at routine care and including patients with pulmonary embolism.
https://acphospitalist.acponline.org/weekly/archives/2017/04/19/3.htm
19 Apr 2017
Updated guideline issued on antithrombotic therapy for VTE
The American College of Chest Physicians issued an updated guideline last week on antithrombotic therapy for venous thromboembolism (VTE), covering topics such as use of direct-acting oral anticoagulants and outpatient treatment of pulmonary embolism.
https://acphospitalist.acponline.org/weekly/archives/2016/01/13/1.htm
13 Jan 2016
Heart failure may be independent risk factor for VTE
Researchers performed a systematic review and meta-analysis to examine the absolute and relative risks (RRs) for venous thromboembolism after hospital admission in patients with heart failure, finding a pooled RR of 1.51 compared to other hospitalized patients.
https://acphospitalist.acponline.org/weekly/archives/2015/12/16/3.htm
16 Dec 2015
Clot recurrence and major bleeds similar with tinzaparin or warfarin, study finds
Cancer patients with venous thromboembolism had similar mortality, but fewer symptomatic deep vein thromboses after 6 months of low-molecular-weight heparin instead of warfarin.
https://acphospitalist.acponline.org/weekly/archives/2015/08/26/1.htm
26 Aug 2015
NSAIDs may increase risk of VTE, meta-analysis finds
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of venous thromboembolism (VTE), a meta-analysis found.
https://acphospitalist.acponline.org/weekly/archives/2014/10/01/4.htm
1 Oct 2014
IVC filters lower PE death risk vs anticoagulants, but raise recurrent VTE risk
Patients with venous thromboembolism (VTE) and significant bleeding risk who got inferior vena cava (IVC) filters had a lower risk of pulmonary embolism (PE)-related death, but a higher risk of recurrent VTE than those on anticoagulants only, a study found.
https://acphospitalist.acponline.org/weekly/archives/2014/03/12/3.htm
12 Mar 2014
Pregnant women admitted to hospital for reasons unrelated to delivery have higher VTE risk
Pregnant women who are admitted to the hospital for reasons not related to delivery have a higher risk of first venous thromboembolism, a new study found.
https://acphospitalist.acponline.org/weekly/archives/2013/11/20/3.htm
20 Nov 2013
Dabigatran noninferior to warfarin for preventing VTE recurrence
In patients who had a previous venous thromboembolism, dabigatran prevented recurrence about as well as warfarin and caused fewer bleeding events, according two new manufacturer-sponsored trials of extended treatment.
https://acphospitalist.acponline.org/weekly/archives/2013/02/27/4.htm
27 Feb 2013
For inpatient VTE prevention, rivaroxaban noninferior to enoxaparin
Rivaroxaban is noninferior to enoxaparin for standard-duration venous thromboembolism (VTE) prophylaxis in acutely ill patients, a new study found.
https://acphospitalist.acponline.org/weekly/archives/2013/02/13/3.htm
13 Feb 2013
VTE risk appears increased in patients with slightly low eGFR, albumin-creatinine ratio
Even mild kidney disease is associated with an increase in risk of venous thromboembolism (VTE), a new review found.
https://acphospitalist.acponline.org/weekly/archives/2012/09/26/5.htm
26 Sep 2012
Aspirin appears to reduce recurrence of VTE after stopping anticoagulants
Aspirin reduced the risk of venous thromboembolism (VTE) recurrence with no apparent increase in major bleeding in patients who had an initial unprovoked VTE and had discontinued anticoagulant treatment, a study found.
https://acphospitalist.acponline.org/weekly/archives/2012/06/06/3.htm
6 Jun 2012
Intervention improved venous thromboembolism prophylaxis
A multi-faceted intervention increased venous thromboembolism (VTE) prophylaxis among medical and surgical patients in an Australian hospital, a new study reported.
https://acphospitalist.acponline.org/weekly/archives/2012/03/14/3.htm
14 Mar 2012